Neoplasm Malignant Clinical Trial
— Small StepsOfficial title:
A Randomized Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer
To examine the efficacy of a 10-week multimodal lifestyle program, versus waitlist control, on cardiorespiratory fitness capacity and body weight in survivors of cancer.
Status | Recruiting |
Enrollment | 54 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Ability to provide informed consent before any trial-related activities - History of any malignancy - Completion of cancer-directed therapy (e.g., surgery, chemotherapy, and radiotherapy) prior to enrollment (patients receiving ongoing endocrine or targeted therapy are eligible to participate) - No evidence of residual or recurrent cancer under active treatment - Age =18 years - Body mass index (BMI) =30 kg/m2 or BMI =27 kg/m2 with one or more treated or untreated weight-related coexisting conditions - Willing to be randomized - Allow the collection and storage of biospecimens and data for future use Exclusion Criteria: - Engaging in =3 purposeful exercise sessions per week, on average, over the past 12 weeks - Significant purposeful weight loss (>11 kg) within the past 12 weeks - Current use of medications or devices for the purpose of weight loss - Metabolic or bariatric surgery within the last year - Cardiovascular, respiratory, or musculoskeletal disease that would prohibit participation in an exercise and weight loss program - Currently pregnant, breastfeeding, or planning to become pregnant with the next 12 weeks - Psychiatric disorders or conditions that would preclude participation in the study intervention - Any other condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the study |
Country | Name | City | State |
---|---|---|---|
United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Pennington Biomedical Research Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cardiorespiratory fitness capacity (co-primary) | Cardiorespiratory fitness (VO2peak) assessed by a symptom-limited cardiopulmonary exercise test. | Baseline, Week 10 | |
Primary | Change in body weight (co-primary) | Bodyweight assessed using a digital scale in a fasting state with an empty bladder, without shoes, and only wearing light clothing. | Baseline, Week 10 | |
Secondary | Change in waist Circumference | Measured midway between the lower rib margin and the iliac crest. | Baseline, Week 10 | |
Secondary | Change in fat Mass | Measured by dual-energy x-ray absorptiometry | Baseline, Week 10 | |
Secondary | Change in systolic blood pressure | Seating, resting for 5 minutes before the measure is taken | Baseline, Week 10 | |
Secondary | Change in diastolic blood pressure | Seating, resting for 5 minutes before the measure is taken | Baseline, Week 10 | |
Secondary | Change in medication use | Medications related to cholesterol, diabetes, and blood pressure | Baseline, Week 10 | |
Secondary | Change in physical and mental quality-of-life | Assessed using the 36-Item Short Form Survey (SF-36) | Baseline, Week 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01156870 -
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
|
Phase 1 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01930552 -
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT01657214 -
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
|
Phase 1 | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Completed |
NCT02575781 -
A Study of SAR428926 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01943838 -
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT03324113 -
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06238687 -
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02435121 -
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
|
Phase 2 | |
Completed |
NCT01985191 -
A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
|
Phase 1 | |
Completed |
NCT01455532 -
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04067388 -
iKnife REIMS Project
|
||
Completed |
NCT01836705 -
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT01140607 -
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
|
Phase 1 | |
Recruiting |
NCT04495790 -
AIMS Cancer Outcomes Study
|
||
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Recruiting |
NCT04733469 -
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
|
N/A | |
Active, not recruiting |
NCT03845166 -
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
|
Phase 1 |